ArticleCell reports. Medicine2023
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors.
Abstract read
In one paragraph
Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Single-cell hdWGCNA identifies checkpoint inhibitor pneumonitis-linked CD4 + T-cell subsets driving immunotherapy response and prognosis in lung cancer.Journal of cancer research and clinical oncology · 2026Article
- Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells but likely not autoantibodies.Science advances · 2026Article
- Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations.The Journal of clinical investigation · 2026Article
- Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trials.Cancer immunology, immunotherapy : CII · 2026Article
- Understanding the Inflammatory Aspect of Osteoarthritis: Lessons from Immune Checkpoint Inhibitors.Journal of clinical medicine · 2026Review
- Omics-based biomarkers of immune-related organ toxicities associated with immune checkpoint inhibitors: a scoping review and evidence map.Frontiers in immunology · 2026Article
- Integrated cellular, proteomic and metabolomic profiling of immune-related adverse events in non-small cell lung cancer.Frontiers in immunology · 2026Article
- Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1/PD-L1 therapy in lung cancer: a literature review.Frontiers in immunology · 2026Review
- Single-cell transcriptomic insights into the immune heterogeneity of immune checkpoint inhibitors related organ toxicities.Frontiers in immunology · 2026Review
- Single-cell profiling of PBMCS reveals an immune signature of irAEs in anti-PD-1-treated acral melanoma patients.Frontiers in immunology · 2026Article
- ICPi-Induced Graves' Disease with Pre-existing Autoimmune Thyroid Disorders: A Case Report and Literature Review.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Exposure-response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy.Frontiers in pharmacology · 2026Review
- Real-world efficacy, safety, and associated biomarkers of cadonilimab in cervical cancer: a prospective observational study.Frontiers in immunology · 2026Observational
- Dysregulated NAMPT signaling underlines the immune-suppressive microenvironment in venous leg ulcers.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Distinct immune cell dynamics associated with immune-related adverse events during combined chemoradiation and immune checkpoint inhibitor therapy.Nature communications · 2025Article
- Hydrophobic complementarity-determining region 3 (CDR3) sequences elucidate the cardiotoxic effects of immune checkpoint inhibitors.Research square · 2025Article
- Tissue-resident microbiota impacts colorectal cancer progression and prognosis.Nature communications · 2025Article
- Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis.Human vaccines & immunotherapeutics · 2025Review
- Uncovering the immune mechanisms underlying the emergence of immunotherapy-induced pneumonitis in lung cancer patients.Nature communications · 2025Article
- Monocyte/macrophage-derived NLRP3 Promotes the Onset and Progression of Ankylosing Spondylitis Via the NOD-like Receptor Pathway.Journal of clinical immunology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Shoiab BukhariColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY 10032, USA.
Brian S HenickColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Robert J WinchesterColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY 10032, USA; Division of Rheumatology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.
Shalom LerrerColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY 10032, USA.
Kieran AdamColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY 10032, USA.
Yevgeniya GartshteynDivision of Rheumatology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.
Rohan ManiarHerbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Ziyan LinApplied Bioinformatics Laboratories and Genome Technology Center, Division of Advanced Research Technologies, NYU School of Medicine, New York, NY 10016, USA.
Alireza Khodadadi-JamayranApplied Bioinformatics Laboratories and Genome Technology Center, Division of Advanced Research Technologies, NYU School of Medicine, New York, NY 10016, USA.
Aristotelis TsirigosApplied Bioinformatics Laboratories and Genome Technology Center, Division of Advanced Research Technologies, NYU School of Medicine, New York, NY 10016, USA.
Mary M SalvatoreDepartment of Radiology, Columbia University Medical Center, New York, NY 10032, USA.
Galina G LagosHerbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Steven L ReinerDepartments of Microbiology & Immunology and Pediatrics, Columbia University Irving Medical Center, New York, NY 10032, USA.
Matthew C DallosHerbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Matthen MathewHerbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Naiyer A RizviHerbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Adam MorColumbia Center for Translational Immunology, Columbia University Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA; Division of Rheumatology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA. Electronic address: am5121@columbia.edu.
Funding
Novel mechanisms regulating PD-1 signaling and functionR01AI125640 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Adam Mor · 2016 to 2026
$4.3MA systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse eventsR01AI175498 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Adam Mor, Robert J Winchester · 2023 to 2026
$2.9MPAG is a novel target in immunotherapyR01AI150597 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOR, ADAM · 2020 to 2024
$2.7MStrategies to predict and overcome resistance to cancer immunotherapyR01CA279268 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STEVEN L REINER · 2023 to 2026
$2.2M(PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockadeR21CA231277 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOR, ADAM · 2019 to 2020
$361kFive-laser Aurora spectral flow cytometerS10OD030282 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CREUSOT, REMI J · 2022 to 2022
$361kNCI NIH HHS R01 CA279268NCI NIH HHS R21 CA231277NIAID NIH HHS R01 AI125640NIAID NIH HHS R01 AI150597NIAID NIH HHS R01 AI175498NIH HHS S10 OD030282
Abstract
PD-1 is an inhibitory receptor in T cells, and antibodies that block its interaction with ligands augment anti-tumor immune responses. The clinical potential of these agents is limited by the fact that half of all patients develop immune-related adverse events (irAEs). To generate insights into the cellular changes that occur during anti-PD-1 treatment, we performed single-cell RNA sequencing of circulating T cells collected from patients with cancer. Using the K-nearest-neighbor-based network graph-drawing layout, we show the involvement of distinctive genes and subpopulations of T cells. We identify that at baseline, patients with arthritis have fewer CD8 T
Indexed as
NeoplasmsT-LymphocytesHumansImmunityImmunotherapySequence Analysis, RNAarthritisautoimmunitycheckpoint inhibitorimmune-related adverse eventsirAEsPD-1pneumonitissingle-cell RNA sequencingT cellsthyroiditis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.